Advanced Ultra-Early Cancer Screening

---

Ultra-early cancer screening uses advanced liquid biopsy technology to detect minute traces of circulating tumor DNA (ctDNA) in your blood. This revolutionary method allows for the identification of cancer signals at the molecular level — long before conventional imaging or symptoms can detect abnormalities.

1. Blood Sample: A simple blood draw is taken in a clinical setting.
2. ctDNA Analysis: The blood is analyzed using next-generation sequencing (NGS) to detect fragmented DNA from potential tumors.
3. Bioinformatics Review: AI-powered software scans for cancer-specific mutations and epigenetic signatures.
4. Report & Interpretation: A detailed report is generated and reviewed by an oncologist or specialist.

This test can screen for dozens of cancer types, including:

• Lung cancer
• Colorectal cancer
• Liver cancer
• Pancreatic cancer
• Breast and ovarian cancer
• Prostate cancer
• Gastric cancer
• And more...

• Non-invasive and pain-free (blood draw only)
• Detects cancer before tumors are visible by imaging
• Improves prognosis through early intervention
• Suitable for annual screening in high-risk individuals
• Customizable to your genetic risk profile

Numerous clinical studies have validated the use of ctDNA testing in cancer detection:

• Circulating Tumor DNA Analysis in Cancer Management – The New England Journal of Medicine
• Advances in Liquid Biopsy Technologies for Cancer Detection – PMC
• Detection and localization of surgically resectable cancers with a multi-analyte blood test – NIH

• Individuals over 40 years old
• People with a family history of cancer
• High-risk individuals (e.g., smokers, heavy alcohol use)
• Executives and high-stress professionals seeking peace of mind